AbbVie Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AbbVie Inc. on June 28, 2022, reporting events that occurred on June 23, 2022. The filing pertains to significant changes in the company's executive leadership structure.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and does not contain financial performance data.
Material Changes
The primary material change reported is the appointment of two senior officers effective June 23, 2022:
- Robert A. Michael: Appointed Vice Chairman and President. He previously served as Vice Chairman, Finance and Commercial Operations and Chief Financial Officer since December 2021.
- Scott T. Reents: Appointed Senior Vice President, Chief Financial Officer. He previously served as Vice President, Tax and Treasury.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the announcement of the executive appointments.
Key Facts for Investor Verification
- Verify the effective date of the leadership transition (June 23, 2022).
- Confirm the new reporting structure with Robert A. Michael as President and Scott T. Reents as CFO.
- Note that this filing does not impact the company's financial statements or debt obligations listed in the header.